Lantus (Insulin Glargine) FDA Label Updates: 2020 to 2026

The direct answer

Insulin glargine (Lantus) is an FDA-approved long-acting basal insulin, first approved in 2000, and its US label has been amended multiple times since 2020 without the addition of a new boxed warning, new contraindication, or Risk Evaluation and Mitigation Strategy. The documented substantive changes in this period are narrower in scope than sometimes described: tightened hypoglycemia and medication-error warning language, pediatric dosing clarification, and administrative cross-references created by the arrival of interchangeable biosimilars (Semglee in 2021, with additional entrants since). Readers should treat any specific numeric claim about post-market surveillance rates, antibody incidence, or state substitution counts as requiring verification against the current FDA label and the FDA's own surveillance publications, since those exact figures are not confirmed in the source material behind this article.

FDA approval history and regulatory baseline

Insulin glargine was approved on June 20, 2000, under NDA 021081, as the first long-acting insulin analog available in the United States, for glycemic control in adults and pediatric patients aged 6 and older with type 1 diabetes, and in adults with type 2 diabetes. By 2020 the label had already accumulated many revisions predating this review window.

The label entering 2020 referenced cardiovascular outcome data from a large randomized trial of basal insulin in people with dysglycemia (commonly referred to as the ORIGIN trial), which is widely reported to have shown a neutral cardiovascular effect for insulin glargine compared with standard care over several years of follow-up. The exact enrollment figure, hazard ratios, and follow-up duration attributed to this trial in older marketing material should be verified against the trial's original publication rather than taken from secondary summaries, including this one.

The FDA's Drugs@FDA database and the FDA Orange Book are the authoritative places to confirm the date and content of any specific label supplement discussed below. Where this article describes a change without an FDA supplement number, that change should be treated as directionally reported rather than independently confirmed here.

2020 to 2021: hypoglycemia and medication-error language

Reporting on this period describes revisions to the Warnings and Precautions section addressing hypoglycemia risk with changes in insulin regimen, and additional instructions for patients and pharmacists to verify the insulin product label before each injection. This kind of change has affected multiple long-acting insulin labels industry-wide, tied to the FDA's ongoing concern about product mix-ups tracked through the FDA Adverse Event Reporting System (FAERS) public dashboard. Reports also describe an expanded hypoglycemia risk-factor list adding adrenal insufficiency alongside renal and hepatic impairment, consistent with general diabetes management guidance published by the American Diabetes Association. The precise supplement number and effective date of each change should be confirmed against the current label text rather than assumed from this summary.

2021: biosimilar interchangeability and its indirect effect on the Lantus label

The FDA's July 2021 approval of Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar insulin was a significant regulatory event. It did not rewrite the clinical content of the Lantus label, but it created pressure for administrative cross-referencing, particularly in the "How Supplied" and patient counseling sections, to distinguish device design and concentration labeling across manufacturers.

General FDA policy on this pathway is described on the agency's biosimilar product information page and in general FDA guidance on interchangeable biological products. This framework establishes (an interchangeable biosimilar may be substituted at the pharmacy level without prescriber authorization, subject to state law) but do not themselves confirm a specific HbA1c difference between Lantus and any biosimilar. Any exact effect-size figure for switching outcomes should be checked against a current systematic review or the biosimilar's own approval package rather than repeated from older marketing summaries.

2022: post-market immunogenicity language

Multiple sources describe a 2022 update to the Adverse Reactions section addressing accumulated post-market immunogenicity data. The available secondary material asserts that real-world antibody formation rates were consistent with clinical trial findings and that no new immunogenicity-driven safety signal was identified. That directional claim is plausible given the drug's decades of use, but the specific numeric rate sometimes attached to it (a rate below a fraction of one event per 10,000 patient-years) is not confirmed against a primary FDA periodic safety update report in the material available for this review and should not be cited as an exact figure without checking the actual PSUR filing or other primary FDA postmarket safety documentation.

Decision framework: what this history should and should not change about your next step

Different readers land on a label-history page like this one for different reasons. The table below separates what is reasonably established from what needs a fresh check, by reader role.

2023: pediatric dosing language

Secondary reporting describes a 2023 label update to the Pediatric Use subsection retaining the age-6-and-older cutoff for type 1 diabetes but adding clearer weight-based starting-dose language, commonly cited as an approximate starting point in the range typically recommended by pediatric endocrinology consensus guidance (roughly 0.1 to 0.3 units/kg/day, titrated to fasting glucose). This range is broadly consistent with how pediatric basal insulin initiation is generally described in the field, but the exact wording adopted in the FDA label, and any specific physiologic claim about insulin sensitivity changes during puberty, should be verified against the current label and the primary pediatric diabetes literature rather than treated as confirmed by this summary.

The instruction that insulin glargine should not be diluted or mixed with other insulin preparations is a longstanding label feature, not a new 2023 addition, though its placement within the pediatric section may have been made more prominent.

2024: real-world surveillance and hypoglycemia monitoring

Reports describe an FDA Sentinel System query examining severe hypoglycemia among long-acting insulin users, including insulin glargine, using electronic health record and claims data. The FDA Sentinel Initiative is a real active-surveillance program capable of this kind of query, and a null or reassuring finding (no statistically meaningful change from pre-2020 rates) would be consistent with the absence of a new boxed warning in this period. However, the specific prescription count, event rate, and p-value sometimes attached to this analysis are not confirmed in the material available for this review. Anyone relying on those exact figures for a clinical or regulatory decision should locate the original Sentinel query report rather than cite this article as the source.

Quotations attributed to named FDA or ADA officials in earlier versions of this kind of summary could not be verified against a traceable, dateable source and have been removed rather than repeated here. If a direct quotation is needed for a future revision, it should be sourced to a specific, checkable transcript, press release, or publication.

2025 to 2026: current status and what might still change

As of this review, no new contraindication, boxed warning, or REMS has been added to the Lantus label since 2020. Two areas are plausible sources of future revision but are not yet confirmed changes: continued FDA attention to concentration-related dosing errors across insulin glargine strengths (U-100 versus U-300), and continued pressure on the reference label's "How Supplied" and patient counseling sections as more interchangeable biosimilars enter the market. The current authoritative source for the live label text is the FDA's own Drugs@FDA system and the National Library of Medicine's DailyMed, not any dated summary article.

What is established, what is plausible, and what is not established

Established: Lantus received original FDA approval in 2000 for the indications listed above. Semglee was approved as the first interchangeable insulin glargine biosimilar in July 2021. No new boxed warning, contraindication, or REMS was added to the Lantus label between 2020 and 2026. General FDA policy on interchangeable biosimilar substitution is publicly documented.

Plausible but not independently confirmed here: Specific numeric findings from post-market immunogenicity review, the 2024 Sentinel hypoglycemia query's exact event rates, and the precise wording changes in each yearly label supplement. These are consistent with how FDA post-market surveillance typically works, but the exact figures require confirmation against primary FDA documents before being cited as fact.

Not established by this article: Individualized hypoglycemia risk, correct starting dose for any specific patient, and whether a particular pharmacy substitution is currently permitted under a specific state's law, since state rules change over time and are not tracked here.

Frequently asked questions

References

1. U.S. Food and Drug Administration. Drug Approvals and Databases: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
2. U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
3. American Diabetes Association. Standards of Care in Diabetes. https://diabetesjournals.org/care
4. U.S. Food and Drug Administration. Biosimilar Product Information. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
5. U.S. Food and Drug Administration. FDA's Sentinel Initiative. https://www.fda.gov/safety/fdas-sentinel-initiative
6. U.S. Food and Drug Administration. Advisory Committees. https://www.fda.gov/advisory-committees

Specific figures such as surveillance rates, antibody percentages, and state substitution counts are reported to vary between studies and have not been independently confirmed here. Readers should consult current prescribing information and primary sources for precise statistics.